AVID BIOSERVICES, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.79 USD | +2.10% |
|
-3.01% | +18.92% |
| Apr. 30 | RBC Lifts Price Target on Avid Bioservices to $8 From $7, Keeps Outperform Rating | MT |
| Apr. 29 | Transcript : Avid Bioservices, Inc., Q3 2024 Earnings Call, Apr 29, 2024 |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.
Strengths
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- Low profitability weakens the company.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +18.92% | 484M | D+ | ||
| -0.28% | 90.59B | A- | ||
| -0.92% | 38.99B | A- | ||
| -10.85% | 34.09B | B- | ||
| +64.20% | 26.38B | A | ||
| -18.76% | 15.02B | C | ||
| -7.50% | 13.17B | B- | ||
| -9.76% | 11.88B | D+ | ||
| -47.31% | 10.65B | B | ||
| +6.97% | 9.25B | B+ |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
-
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- CDMO Stock
- Ratings Avid Bioservices, Inc.
